INHIBIKASE THERAPEUTICS INC (IKT) Stock Price, Quote, News and Overview
NASDAQ:IKT - Nasdaq - US45719W2052 - Common Stock - Currency: USD
IKT Quote, Performance and Key Statistics
2.97
-0.29 (-8.9%)
The current stock price of IKT is 2.97 USD. In the past month the price increased by 4.95%. In the past year, price increased by 38.78%.
IKT Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About IKT
Company Profile
Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company, which engages in developing protein kinase inhibitor therapeutics to modify the course of Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. The company is headquartered in Atlanta, Georgia and currently employs 8 full-time employees. The company went IPO on 2020-12-23. The firm is focused on developing therapeutics for Parkinson’s disease and related disorders. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its lead program risvodetinib (also known as IkT-148009), an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of Parkinson’s disease inside and outside the brain as well as other diseases that arise from Ableson Tyrosine Kinases. Its multi-therapeutic pipeline is pursuing Parkinson’s-related disorders of the brain and GI tract, orphan indications related to Parkinson’s disease such as Multiple System Atrophy, and drug delivery technologies for kinase inhibitors such as IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate. The Company’s RAMP medicinal chemistry program has identified a number of follow-on compounds to IkT-148009 to be potentially applied to other cognitive and motor function diseases of the brain.
Company Info
INHIBIKASE THERAPEUTICS INC
3350 Riverwood Parkway Se, Suite 1900
Atlanta GEORGIA 30339 US
CEO: Milton H. Werner
Employees: 9
Company Website: https://www.inhibikase.com/
Investor Relations: http://www.inhibikase.com/investors
Phone: 16783923419
INHIBIKASE THERAPEUTICS INC / IKT FAQ
What is the stock price of INHIBIKASE THERAPEUTICS INC today?
The current stock price of IKT is 2.97 USD. The price decreased by -8.9% in the last trading session.
What is the ticker symbol for INHIBIKASE THERAPEUTICS INC stock?
The exchange symbol of INHIBIKASE THERAPEUTICS INC is IKT and it is listed on the Nasdaq exchange.
On which exchange is IKT stock listed?
IKT stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for INHIBIKASE THERAPEUTICS INC stock?
7 analysts have analysed IKT and the average price target is 8.16 USD. This implies a price increase of 174.75% is expected in the next year compared to the current price of 2.97. Check the INHIBIKASE THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is INHIBIKASE THERAPEUTICS INC worth?
INHIBIKASE THERAPEUTICS INC (IKT) has a market capitalization of 199.55M USD. This makes IKT a Micro Cap stock.
How many employees does INHIBIKASE THERAPEUTICS INC have?
INHIBIKASE THERAPEUTICS INC (IKT) currently has 9 employees.
What are the support and resistance levels for INHIBIKASE THERAPEUTICS INC (IKT) stock?
INHIBIKASE THERAPEUTICS INC (IKT) has a support level at 2.38 and a resistance level at 3.27. Check the full technical report for a detailed analysis of IKT support and resistance levels.
Is INHIBIKASE THERAPEUTICS INC (IKT) expected to grow?
The Revenue of INHIBIKASE THERAPEUTICS INC (IKT) is expected to decline by -100% in the next year. Check the estimates tab for more information on the IKT EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy INHIBIKASE THERAPEUTICS INC (IKT) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of IKT, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of IKT, evaluating the profitability, health, valuation and growth aspects
- INHIBIKASE THERAPEUTICS INC (IKT) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- INHIBIKASE THERAPEUTICS INC (IKT) Sales and EPS estimates to see what analysts future expectations are.
- INHIBIKASE THERAPEUTICS INC (IKT) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- INHIBIKASE THERAPEUTICS INC (IKT) Insider and Institutional Ownership to learn about the owners and their transactions.
- INHIBIKASE THERAPEUTICS INC (IKT) Stock Chart to make your own analysis
- INHIBIKASE THERAPEUTICS INC (IKT) Latest news and press-releases to stay up to date.
Does INHIBIKASE THERAPEUTICS INC (IKT) stock pay dividends?
IKT does not pay a dividend.
When does INHIBIKASE THERAPEUTICS INC (IKT) report earnings?
INHIBIKASE THERAPEUTICS INC (IKT) will report earnings on 2025-03-25, after the market close.
What is the Price/Earnings (PE) ratio of INHIBIKASE THERAPEUTICS INC (IKT)?
INHIBIKASE THERAPEUTICS INC (IKT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.68).
What is the Short Interest ratio of INHIBIKASE THERAPEUTICS INC (IKT) stock?
The outstanding short interest for INHIBIKASE THERAPEUTICS INC (IKT) is 2.04% of its float. Check the ownership tab for more information on the IKT short interest.
IKT Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to IKT. When comparing the yearly performance of all stocks, IKT is one of the better performing stocks in the market, outperforming 91.38% of all stocks.
IKT Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to IKT. IKT has a bad profitability rating. Also its financial health evaluation is rather negative.
IKT Financial Highlights
Over the last trailing twelve months IKT reported a non-GAAP Earnings per Share(EPS) of -2.68. The EPS increased by 33.17% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -447.01% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
IKT Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to IKT. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of 74.44% and a revenue growth -100% for IKT